Analysts forecast that Novo Nordisk A/S (NYSE:NVO) will report earnings of $0.56 per share for the current quarter, Zacks reports. Two analysts have made estimates for Novo Nordisk A/S’s earnings. The lowest EPS estimate is $0.54 and the highest is $0.60. Novo Nordisk A/S reported earnings per share of $0.60 in the same quarter last year, which indicates a negative year-over-year growth rate of 6.7%. The firm is scheduled to announce its next earnings report before the market opens on Wednesday, August 9th.

On average, analysts expect that Novo Nordisk A/S will report full-year earnings of $2.36 per share for the current fiscal year, with EPS estimates ranging from $2.31 to $2.43. For the next financial year, analysts forecast that the firm will post earnings of $2.51 per share, with EPS estimates ranging from $2.34 to $2.67. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side analysts that follow Novo Nordisk A/S.

Several equities research analysts recently issued reports on NVO shares. Zacks Investment Research downgraded Novo Nordisk A/S from a “hold” rating to a “sell” rating in a research note on Wednesday, April 19th. BidaskClub downgraded Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Thursday, June 29th. Finally, TheStreet raised Novo Nordisk A/S from a “c+” rating to a “b-” rating in a research note on Tuesday, May 2nd. Five research analysts have rated the stock with a sell rating, seven have issued a hold rating and four have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of $53.00.

Shares of Novo Nordisk A/S (NVO) traded up 8.31% during midday trading on Wednesday, hitting $44.57. 3,637,672 shares of the company were exchanged. The stock has a market capitalization of $111.24 billion, a price-to-earnings ratio of 18.33 and a beta of 0.63. Novo Nordisk A/S has a 52-week low of $30.89 and a 52-week high of $50.30. The company has a 50-day moving average price of $42.86 and a 200-day moving average price of $38.45.

Several large investors have recently bought and sold shares of NVO. Renaissance Technologies LLC increased its stake in Novo Nordisk A/S by 17.7% in the first quarter. Renaissance Technologies LLC now owns 16,409,200 shares of the company’s stock worth $562,507,000 after buying an additional 2,463,300 shares during the period. Bank of America Corp DE increased its stake in Novo Nordisk A/S by 3.2% in the first quarter. Bank of America Corp DE now owns 12,102,582 shares of the company’s stock worth $414,876,000 after buying an additional 380,536 shares during the period. Fisher Asset Management LLC increased its stake in Novo Nordisk A/S by 12.9% in the second quarter. Fisher Asset Management LLC now owns 11,690,997 shares of the company’s stock worth $501,427,000 after buying an additional 1,331,992 shares during the period. Folketrygdfondet increased its stake in Novo Nordisk A/S by 13.2% in the second quarter. Folketrygdfondet now owns 6,914,192 shares of the company’s stock worth $296,550,000 after buying an additional 803,608 shares during the period. Finally, State Street Corp increased its stake in Novo Nordisk A/S by 64,406.4% in the first quarter. State Street Corp now owns 5,593,351 shares of the company’s stock worth $191,740,000 after buying an additional 5,584,680 shares during the period. 6.40% of the stock is owned by institutional investors.

WARNING: “Analysts Anticipate Novo Nordisk A/S (NVO) Will Announce Earnings of $0.56 Per Share” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this news story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The original version of this news story can be accessed at https://www.thecerbatgem.com/2017/08/19/analysts-anticipate-novo-nordisk-as-nvo-will-announce-earnings-of-0-56-per-share-updated.html.

About Novo Nordisk A/S

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company’s diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs.

Get a free copy of the Zacks research report on Novo Nordisk A/S (NVO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Novo Nordisk A/S (NYSE:NVO)

Receive News & Stock Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related stocks with our FREE daily email newsletter.